文献速递肿瘤 PET/CT核素与放射性配体治疗

头颈癌放疗中定量影像生物标志物预测反应的系统综述与荟萃分析

Quantitative mid-treatment imaging biomarkers for response prediction after radiotherapy in head and neck cancer: a systematic review and meta-analysis.
PubMed 文献 · EJNMMI Res · 2026-06-06

荟萃分析显示,相对治疗中参数的合并AUC为0.796,高于绝对治疗中参数(AUC 0.686)和基线参数(AUC 0.736),但相对与基线间差异未达统计学显著。结论支持相对治疗中影像生物标志物在适应性放疗中的潜在作用。

要点

  • 相对治疗中影像参数的预测性能优于绝对治疗中参数(AUC 0.796 vs 0.686)。
  • 相对治疗中参数与基线参数的AUC差异未达统计学显著。
  • 扩散加权MRI的ΔADCmean和FDG-PET的ΔMTV、ΔTLG预测一致性最高。

核心结论

  • 相对治疗中影像生物标志物预测性能优于基线及绝对测量,支持其在适应性放疗中的潜在作用。
  • 需前瞻性多中心研究、标准化成像协议及外部验证以推动临床转化。

研究设计与样本

  • 系统综述与荟萃分析,检索2005至2023年PubMed、EMBASE、Scopus和Cochrane数据库,遵循预注册PROSPERO方案。

主要发现

  • 相对治疗中参数的合并AUC为0.796(95%CI:0.762-0.831)。
  • 绝对治疗中参数的合并AUC为0.686(95%CI:0.628-0.745)。
  • 基线参数的合并AUC为0.736(95%CI:0.688-0.785),数值低于相对治疗中参数但差异未达统计学显著。
  • 扩散加权MRI的ΔADCmean和FDG-PET的ΔMTV、ΔTLG为预测一致性最高的模态。

关键数值与推荐

  • 相对治疗中参数合并AUC 0.796(95%CI:0.762-0.831)。
  • 绝对治疗中参数合并AUC 0.686(95%CI:0.628-0.745)。
  • 基线参数合并AUC 0.736(95%CI:0.688-0.785)。

临床怎么用

  • 相对治疗中影像参数(如ΔADCmean、ΔMTV、ΔTLG)具有内部自归一化和跨平台可重复性优势,可用于适应性放疗策略的风险分层。
  • 临床转化前需标准化成像协议并开展前瞻性多中心外部验证。

局限性

  • 相对治疗中参数与基线参数的AUC差异未达统计学显著。
  • 需标准化成像协议和外部验证以支持临床转化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To systematically review and meta-analyse the prognostic value of quantitative mid-treatment imaging biomarkers for predicting locoregional tumour control in patients undergoing definitive radiotherapy for mucosal head and neck squamous cell carcinoma. MAIN BODY: A systematic literature search (2005-2023) was conducted in PubMed, EMBASE, Scopus, and Cochrane databases according to a pre-registered PROSPERO protocol. Studies evaluating quantitative imaging features derived from CT, MRI, or PET during radiotherapy were included. Imaging features were grouped as baseline, absolute mid-treatment, or relative mid-treatment (delta) parameters. A random-effects meta-analysis was performed on studies reporting receiver operating characteristic (ROC)-based area under the curve (AUC) values. Forty-one studies encompassing 1654 patients were included. Seventeen studies (n = 612 patients) reported sufficient data for meta-analysis. The pooled AUC for relative mid-treatment parameters was 0.796 (95% CI: 0.762-0.831), demonstrating higher predictive performance than absolute mid-treatment parameters (AUC 0.686; 95% CI: 0.628-0.745). Baseline parameters showed moderate predictive ability (AUC 0.736; 95% CI: 0.688-0.785), and while numerically lower than relative mid-treatment parameters, this difference did not reach statistical significance. Diffusion-weighted MRI (ΔADCmean) and FDG-PET (ΔMTV, ΔTLG) emerged as the most consistently predictive modalities. Relative measures offer practical advantages, including internal self-normalisation and improved reproducibility across imaging platforms. CONCLUSIONS: Relative mid-treatment imaging biomarkers demonstrate superior predictive performance compared to baseline and absolute measures, supporting their potential role in adaptive radiotherapy strategies. Further prospective multi-centre studies with standardised imaging protocols and external validation are essential for clinical translation.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Trada Y, T Lee M, Jameson MG, et al. Quantitative mid-treatment imaging biomarkers for response prediction after radiotherapy in head and neck cancer: a systematic review and meta-analysis. EJNMMI Res. 2026. PMID: 42250069. doi:10.1186/s13550-026-01446-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。